bluuebunny/crossref_metadata_2025_split huggingface dataset:
958 – Efficacy Of Lisdexamfetamine Dimesylate In Children And Adolescents With Attention-deficit/hyperactivity Disorder: Effect Of Age, Sex And Baseline Disease Severity
Authors: Lecendreux M. , Banaschewski T. , Soutullo C. , Johnson M. , Zuddas A. , Anderson C. , Civil R. , Higgins N. , Bloomfield R. , Squires L. , Coghill D. 
Published: July 2013

IntroductionIn a European, phase 3 study (SPD489-325), lisdexamfetamine dimesylate (LDX) was more effective than placebo in improving symptoms and global functioning in children and adolescents with attention-deficit/hyperactivity disorder (ADHD).Objectives and aimsTo evaluate the impact of age, sex and baseline disease severity on efficacy outcomes in SPD489- 325.MethodsThis 7-week, double-blind, parallel-group, dose-optimized study enrolled patients aged 6-17 years with ADHD. Patients were randomized (1:1:1) to once-daily LDX (30, 50 or 70mg/day), osmotic-release oral system methylphenidate (OROS-MPH; 18, 36 or 54mg/day) or placebo. Efficacy outcomes were analysed in patients dichotomized by age (6-12 years [n=229] or 13-17 years [n=88]), sex (male [n=255] or female [n=62]) and baseline ADHD Rating Scale version IV (ADHD-RSIV) total score (28-41 [n=161] or 42-54 [n=152]). Endpoint was the last on-treatment visit with a valid assessment.ResultsAt endpoint, differences (active-placebo) in least-squares mean changes from baseline in ADHD-RS-IV total scores were statistically significant in all age, sex and ADHD-RS-IV total score subgroups for LDX (p< 0.001; effect sizes, 1.68-2.26) and OROS-MPH (p< 0.01; effect sizes, 0.88-1.46). Proportions of patients with a Clinical Global Impressions-Improvement rating of 1 (very much improved) or 2 (much improved) were statistically significantly greater than placebo at endpoint in all subgroups receiving LDX (p< 0.01) and in all subgroups except females receiving OROS-MPH (p< 0.05).ConclusionsLDX showed greater efficacy than placebo in children and adolescents with ADHD, regardless of their age, sex or baseline disease severity.Supported by: Funding from Shire Development LLC.
972 – Difficulties In Cognitive And Social Functioning Of a Patient With Bipolar Disorder
Authors: Sobieraj A. , Wylezek L. , Krysta K. 
Published: July 2013

Bipolar disorder may coexists with cognitive deficits, which may be the one of the core symptoms of the disease. Additional, independent organic changes in the brain may appear, which still deteriorate the cognitive and social function of a patient. The objective of our study was to show how the above impairments disorder influenced patient's life quality. 57-year treated psychiatrically for bipolar disorder was described. During his treatment and diagnostics it turned out that he also suffered from dementia and progressing cognitive impairment.Our case report shows that there exists the dependence between the deterioration of the cognitive impairment caused by the bipolar disorder and increasing level of the patient's quality of life. The result of our investigation is consistent with a number of other studies connected with cognitive functioning in patient with bipolar disease.
975 – Art, Religion And Psychosis
Authors: Zullo L. 
Published: July 2013

IntroductionArt and Religion have accompanied the history of human kind since primordial times, undergoing changes with evolution, being interconnected or separated in antithesis in some historical periods. Nevertheless both are eliciting the idea of “Sublime” affecting in a greater or lesser degree the life of individuals in our society. A curious interconnection with psychosis is seen in two peculiar conditions: Stendhal and Jerusalem syndromes.ObjectivesStarting from the consideration of Art and Religion in the Idealistic philosophy the relationship between Stendhal and Jerusalem syndromes, which lead to acute transient psychotic episodes in tourists with psychic and somatic symptoms, is examined.AimsThis work aims to spread the knowledge about the two syndromes, to highlight analogies between them, and finally to summarize and show a possible connection between the modern findings in neuroaesthetics and Stendhal syndrome.MethodThe work is of qualitative type and mainly descriptive: all the existing evidence on the topic and with possible connections to it was brought together, summarised, and compared leading to new possible ideas for the future.ResultsA hypothetical psycho-pathophysiological mechanism is proposed, based on the psychoanalysis, psychology, genetic, and the new findings in neuroaesthetic (especially connected to Stendhal syndrome), but more research is needed.ConclusionThe influence of Art and Religion culminating in Stendhal syndrome and Jerusalem syndrome, based on their comparison, could be regarded as “tourist syndromes” or as a “tourist's transient psychotic episode” differentiating the object of psychosis as Art in the first and Religion in the second.
1012 – Evaluation Of a Risk-scale For Anticholinergic Side-effects In Elderly Psychiatric Inpatients
Authors: Hefner G. , Fellgiebel A. , Hiemke C. 
Published: July 2013

IntroductionMany commonly prescribed drugs have anticholinergic properties which can induce side-effects e.g. delirium, especially in an ageing brain with increased sensitivity. Risk-assessment before starting therapy may prevent such sideeffects.ObjectivesWe rated anticholinergic pharmacological properties of prescribed medication and compared the theoretical risk with side-effects in clinical practice.AimsThe scale should improve the safety of pharmacotherapy in gerontopsychiatry.MethodsBased on five publications that considered anticholinergic properties of drugs, a risk-scale was established. Riskpoints for all drugs were summarized to a total score. Patients were selected from TDM-requests and data on patients’ sideeffects obtained from medical files. Reported anticholinergic side-effects including delirium were assessed retrospectively by the UKU-rating scale. Using linear regression and Spearman's correlation-analysis a possible correlation between risk-score points and severity of side-effects was determined.ResultsThe screened sample consisted of 53 patients. 38 patients aged from 64 to 89 years (mean 74±6, 63.2% women) could be included for analysis. They had 93 plasma-level determinations (mean 2.4 requests per patient). According to their medication, patients attained by mean 4.51±2.98 risk-points (range 0-16). Mean UKU severity-index of side-effects was 0.81 (±0.99). Risk-points correlated significantly with observed anticholinergic side-effects and delirium (R2=.631, P< 0.001, CI 95%). Spearman correlation-coefficient was 0.731 (P< 0.01, CI 95%).ConclusionsSince the established risk-scale correlated well with reported anticholinergic side-effects we recommend to implement this in the planning of psychopharmacological treatment to improve the safety of pharmacotherapy in gerontopsychiatry. For practical reasons it should be amalgamated with therapeutic drug monitoring as Geronto-TDM.
1017 – Long-term Outcome Of a Multidisciplinary Rehabilitation Program For Chronic Fatigue Syndrome: a One-year Follow-up Study
Authors: Coremans E.L. , Vause M. 
Published: July 2013

ObjectiveTo evaluate the long-term outcome of a multidisciplinary rehabilitation program for patients with chronic fatigue syndrome.Method98 patients fulfilling chronic fatigue syndrome criteria (Fukuda) participated at a six-month CBT associated with GET based on adaptive pacing strategy in a group therapy and were included in a prospective outcome study at the university outpatient Chronic Fatigue Reference Center.MeasuresMultidimensional assessments at baseline, after treatment and at 6 and 12 months follow-up : Checklist Individual Strength; Epworth Sleepiness Scale; Pittsburgh Sleep Quality Index; HADS; Symptom Checklist; Short Form General Health Survey ands Self Efficacy Scale.ResultsAfter the revalidation program, subjective outcome parameters as fatigue severity, concentration troubles, somatic complaints, sleep disturbances and behavioral consequences of fatigue as activity reduction improve significantly (p< 0,001). The QoL related to health perception, measured in items as vitality, role-physical limitations and social functioning, also improve significantly (p< 0,001). Treatment doesn’t change HADS-scales but the scores don’t differ significantly from a healthy population at baseline. At 6 and 12 months follow-up, we didn’t notice significant decreases in outcome results. Significant improvements correlate significantly with an increase of sense of control of the symptoms (Self Efficacy Scale).ConclusionsSymptoms, health-related QoL and psychosocial functioning in patients with chronic fatigue syndrome improve after a six-month multidisciplinary rehabilitation program. The one-year follow-up study without any therapeutic intervention proves that outcome can be maintained. The correlation between the persisting outcome results and the increase of Self Efficacy will be discussed.
1026 – Electroconvulsive Therapy As An Effective Treatment In Neuroleptic Malignant Syndrome: Purposely a Case
Authors: Ogando Portilla N. , Martinez Cortés M. , del Nido Varo L. , Torío Palmero I. , Ortega Bernardo M.C. , Jimenez-Arriero M.A. 
Published: July 2013

IntroductionNMS is an infrequent, life-threatening neurologic emergency usually associated with the use of neuroleptics and some other agents that affect central dopaminergic neurotransmission. Because of its low frequency, heterogeneous nature and clinical variability it might be difficult to diagnose.ObjetivesTo identify risk factors to develop a NMS and to set effective treatments.MethodsLiterature search was performed in PubMed and UpToDate. Report of a case at our center: 69 year old man with psychotic depression which do not improve with optimal doses of SSRIs, Mirtazapine and Benzodiazepines. Olanzapine (10mg) was added and symptoms compatible with a neuroleptic malignant syndrome were appeared. Supportive care was needed because of medical complications. A treatment with bromocriptine, sertraline, lorazepam and dantrolene was begun with little improvement. It was decided to begin ECT.ResultsIt was applied a ECT therapy (12 bifrontotemporal sessions, 380mCu) with a high and effective response. Pshycosis and pshycomotor symptoms disappeared and depression decreased significantly.DiscussionHence a high index of suspicion is needed in the diagnosis of NMS in order to reduce mortality and secuelae. Differential diagnosis must be performed with confusional states due to medical cause, catatonia, serotoninergic syndrome and other neurologic states. As for the treatment, general support meassures and several farmacologic options have been used, though none of them have proved to decrease mortality. ECT remains a good option for improvement of the syndrome as well as the pychiatric condition. No systematic clinical trials evaluating the efficacy of different treatments have been done so far.
1033 – Restless Legs Syndrome Induced By The Combined Use Of Quetiapine And Venlafaxine
Authors: Michopoulos I. , Gournellis R. , Ferentinos P. , Douzenis A. , Tsaklakidou D. , Kaparoudaki A. , Papadopoulou M. , Papazahos C. , Liappas I. 
Published: July 2013

IntroductionRestless legs syndrome (RLS) is a sensorimotor disorder characterized of an urge to move the legs during periods of rest or inactivity, such as lying or sitting.ObjectivesDrug-induced RLS, still remains an under- or misdiagnosed condition.AimsWe present a case of a female patient, who received a combination of low dose of quetiapine in addition to venlafaxine and manifested RLS.MethodsOur patient was admitted because of a mixed episode of bipolar II disorder. At admission she was under valproic (1.5gr/QD, plasma levels: 79mg/litre), topiramate (100mg/QD) and venlafaxine (300mg/BID). Quetiapine 150 mg/QD was started at bed time and within 48 hours the patient showed RLS. The physical, neurological and laboratory examination was normal.ResultsThe tapering of venlafaxine resulted in the elimination of RLS within 48 hours. After discharge the patient remained in a normothymic state, without RLS, taking valproate 1,5gr/QD, topiramate 100mg/QD and quetiapine 150mg/QD. After 6 months, because of depression, quetiapine was reduced to 100mg/QD and venlafaxine 75mh/QD was added. The previously described RLS symptoms emerged again within 48 hours. This time the tapering of quetiapine and its substitution by olanzapine 10 mg/QD resulted in a prompt and complete elimination of RLS symptoms.ConclusionsNeither quetiapine alone, nor venlafaxine alone induced RLS to our patient. Clinicians should not overlook the possibility a RLS to be induced by quetiapine-vanlafaxine combination. The removal of one of the two drugs might be beneficial in the RLS's successful treatment.
1040 – A Study Of Effectiveness Of Structured Group Psychoeducation For Bipolar Patients. a Controlled Trial In Italy
Authors: Candini V. , Buizza C. , de Girolamo G. , Ferrari C. , Caldera M.T. , Nobili G. , Pioli R. , Sacchetti E. , Saviotti F.M. , Seggioli G. , Zanini A. 
Published: July 2013

BackgroundRecent reviews of evidence-based guidelines for the clinical management of Bipolar Disorders (BD) have recommended that “all patients with BD should be offered group or individual psychoeducation” to prevent relapse, improve treatment adherence, quality of life and functioning.The present study aimed at evaluating the psychoeducation in routine mental health.MethodsOne hundred and two outpatients were recruited from two Italian DMHs. Inclusion criteria were a lifetime diagnosis of BD type I or II assessed by SCID-I, being euthymic for at least 3 months. Exclusion criteria were a DSM-IV Axis I comorbidity, mental retardation (IQ < 70), organic brain damage. All subjects received standard psychiatric care, with standard pharmacological treatment; one group received additional 21 weekly sessions of psychoeducation group, according to Colom and Vieta model.ResultsData show that the number of patients hospitalized during the 1-year follow-up, the mean number of hospitalizations per patient and the mean number of days in hospital were significantly lower for psychoeducated patients.ConclusionOur study supports the view that group psychoeducation is an efficacious intervention to prevent patients’ hospitalization and decrease hospital days in pharmacologically treated patients with bipolar disorder, also in routine clinical settings. The results seem to confirm that the psychoeducation promotes an improvement in the course of illness, avoiding acute phases, and producing a greater stabilization of the disease and consequently an improvement in quality of life in people with BD.
1043 – Expression Of Obesity Related Genes And Leptin Serum Levels Are Decreased In Turkish Schizophrenia Patients, Case-control Study
Authors: Akan G. , Ozgen O. , Colak A. , Acar S. , Oncu F. , Yesilbursa D. , Turkcan S. , Atalar F. 
Published: July 2013

Antipsychotic medications can induce metabolic abnormalities (weight gain) in schizophrenia (SCH). Leptin receptor (LEPR), leptin (LEP) and peroxysome proliferator-activated receptor g2 (PPARg2) are the potential genetic determinants which might be liable of the metabolic dysregulation. The aim of this study was to evaluate the effect of LEP c.-2548G>A, LEPR p.Q223R polymorphisms and the impact of mRNA levels of LEP, LEPR, and PPARg2 along with the serum leptin levels on metabolic adversities in SCH patients (n=132) and controls (n=114).MethodsMetabolic profiles, LEP, LEPR gene polymorphisms and the gene expressions of LEP, LEPR and PPARg2 were studied in SCH patients and controls.ResultsBMI, cholesterol and fasting glucose levels were higher in SCH patients compared to controls. LEP c.-2548 (GA+AA) genotypes were two fold lower in SCH patients versus controls (p< 0.05), and no significant difference was observed in LEPR p.Q223R genotypes. Interestingly, leptin serum levels were lower in SCH patients compared to controls (p< 0.05). Leptin, leptin receptor and PPARg2 gene expressions were found to be decreased in SCH patients compared to controls (p< 0.001, p< 0.001 and p≤0.05, respectively).ConclusionLeptin receptor, leptin and PPARg2 genes could be potential risk factors in developing metabolic adversities in SCH.
1056 – Comparative Effectiveness Of Long-term Treatment With Atypical Antipsychotics In Patients With Schizophrenia
Authors: Pikalov A. , Citrome L. , Hsu J. , Werner P. , Cucchiaro J. , Loebel A. 
Published: July 2013

IntroductionLong-term head-to-head studies comparing atypical antipsychotics are important for clinical decision making.ObjectivesTo evaluate long-term treatment of schizophrenia with lurasidone (LUR) vs. quetiapine XR (QXR; Study 234), or risperidone (RIS; Study 237).AimsTo assess efficacy and safety of lurasidone relative to other antipsychotics.MethodsIn study 234(efficacy and safety), subjects received 12 months double-blind, flexible-dose lurasidone(40-160 mg/day) or QXR(200-800 mg/day) after completing a 6 week, randomized, double-blind, placebo-controlled trial with LUR or QXR. In Study 237 (safety) clinically stable adult outpatients received 12-months double-blind treatment with flexible-dose LUR 40-120 mg/day or RIS 2-6 mg/day.ResultsStudy 234: continued treatment of LUR responders (n=139) reduced relapse risk by 27.2% vs. continued QXR treatment of QXR responders (n=79). Hospitalization risk was 56.7% lower with LUR vs. QXR. More LUR subjects achieved sustained remission vs. QXR (61.9% vs. 46.3%; p=0.043; 12 months, LOCF), and lower all-cause discontinuation (48% vs 61%). Triglycerides were reduced with LUR; total and LDL cholesterol were unchanged or reduced. Median prolactin change was +0.6 for LUR vs. -0.7 ng/mL for QXR. Study 237: clinically significant weight gain was observed with LUR 13%) vs. RIS (19%) with median change in prolactin 0.4 vs. 14.8 ng/mL, respectively. Comparable efficacy was observed for LUR and RIS (change from baseline in PANSS total score:-4.7 vs. -6.5, and CGI-Severity score:-0.4 vs. -0.4, respectively).ConclusionThe results of these two 12-month trials suggest that lurasidone is safe and well-tolerated with efficacy comparable to quetiapine XR and risperidone for long-term treatment of schizophrenia.
1079 – Effects Of Psychological Distress And Social Support On Mental Fitness Among Patients Of Mental Health Services
Authors: Park W.-R. , Yu J.-C. , Lee M.-R. , Kim D.-Y. 
Published: July 2013

IntroductionLife events and accompanying psychological and behavioral reactions frequently have an impact upon people's daily lives and are believed to predispose them to disease. Psychological stressors impact many physiological and pathological disease outcomes, including mental illness. Positive social interactions have in turn been shown to exert powerful beneficial effects on health outcomes and longevity.ObjectivesThe Objective of this study was to analyze the relationships of Psychological Distress, Social Support, and Mental Fitness among patients of mental health services.AimsThis article aims to discuss the evidence supporting the mediating effect of social support between psychological stress and mental health.MethodsThis study was performed on patients who visited the mental health services in Daejeon from October to December 2011. In total, 395 patients were evaluated with Mental Fitness Scale, Kessler Psychological Distress Scale(KPDS), and Multidimensional Scale of Perceived Social Support(MSPSS).ResultsCorrelations among variables of psychological distress and social support on subordinate variable of mental fitness of patients were significant. The result of the regression analysis, psychological distress and social support have a positively significant influence on mental fitness of patients. social support showed mediating effects between psychological distress and mental fitness.ConclusionThese results suggest that health care providers ought to seek social support for patients, in order to provide positive mental fitness of patients.
1082 – 40-week, Randomized, Double-blind, Placebo-controlled, Multicenter, Efficacy And Safety Study Of Methylphenidate Hydrochloride Modified Release (mph-la) In Adults With Attention Deficit Hyperactivity Disorder (adhd)
Authors: Huss M. , Ginsberg Y. , Philipsen A. , Tvedten T. , Arngrim T. , Greenbaum M. , Carter K. , Chen C.-W. , Kumar V. 
Published: July 2013

IntroductionRecent epidemiology studies have reported the prevalence of adult ADHD to be approximately 4%, however approved treatments are limited.ObjectivesPrimary objectives were to confirm the clinically-effective and safe dosage range of MPH-LA in adults with ADHD and evaluate the 6-month maintenance of effect.MethodsTreatment Period (TP) 1: Patients were randomized to double-blind placebo, MPH-LA 40, 60, or 80 mg/day for 9- weeks (3-week titration, 6-week fixed-dose) to evaluate change in DSM-IV ADHD-RS and Sheehan Disability Scale (SDS) total score in TP1. TP2: 5-week titration to individual optimal dose. TP3: Patients were randomized to their optimal dose or placebo for 6-months double-blind withdrawal period to evaluate percentage of treatment failures during TP3.ResultsImprovement from baseline in total score on the DSM-IV ADHD-RS and SDS was significantly greater than placebo for all MPH-LA dose levels (table). Patients treated with MPH-LA had significantly lower treatment failure rates (21.34%) compared to placebo in TP3 (49.6%; odds-ratio (95%CI=0.3 (0.2, 0.4); p< 0.0001). The safety results were consistent with the established safety profile for MPH-LA.[Improvement by week 9: DSM-IV ADHD-RS and SDS].N=Full Analysis Set for TP1 (All randomized patients receiving one dose of study drug in TP1)MPH-LA (40mg) (N=174)MPH-LA (60mg) (N=175)MPH-LA (80mg) (N=179)Placebo (N=172)Attention-Deficit/Hyperactivity Disorder Rating scale (DSM-IV ADHD-RS) (n)160155156161LS Mean15.4514.7116.369.35LS mean difference from placebo (95% CI)6.10 (3.68, 8.53)36 (2.92, 7.79)7.01 (4.59, 9.42) p valuep<0.0001p<0.0001p<0.0001 Sheehan Disability Scale (n)151146148152LS Mean5.894.906.473.03LS mean difference from placebo (95% CI)2.86 (1.33, 4.39)1.87 (0.33, 3.41)3.44 (1.91, 4.97) p value0.00030.0176<0.0001 Significance level (gatekeeping procedure)0.01670.02080.0313 ConclusionsMPH-LA administered at 40-80mg/day demonstrated superior ADHD symptom control and reduction in functional impairment compared to placebo and demonstrated maintenance of effect over 6 months. No unexpected adverse events were observed.